SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-085166
Filing Date
2022-03-25
Accepted
2022-03-25 16:16:08
Documents
15
Period of Report
2022-03-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d315548d8k.htm   iXBRL 8-K 29739
2 EX-1.1 d315548dex11.htm EX-1.1 194787
3 EX-5.1 d315548dex51.htm EX-5.1 10314
7 GRAPHIC g315548dsp41.jpg GRAPHIC 3225
  Complete submission text file 0001193125-22-085166.txt   425595

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eigr-20220325.xsd EX-101.SCH 2861
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20220325_lab.xml EX-101.LAB 18759
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20220325_pre.xml EX-101.PRE 11714
9 EXTRACTED XBRL INSTANCE DOCUMENT d315548d8k_htm.xml XML 3565
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 22771570
SIC: 2836 Biological Products, (No Diagnostic Substances)